<DOC>
	<DOCNO>NCT00014508</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy . Sometimes transplanted cell reject body 's tissue . Peripheral stem cell transplantation person 's stem cell follow donor peripheral stem cell transplantation may prevent happen . PURPOSE : Phase II trial study effectiveness combine chemotherapy autologous peripheral stem cell transplantation donor peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine incidence early mortality patient multiple myeloma treat melphalan autologous peripheral blood stem cell ( PBSC ) transplantation follow fludarabine , cyclophosphamide , allogeneic PBSC transplantation . - Determine incidence early allogeneic graft failure ( day 100 allogeneic PBSC transplantation ) incidence severe acute graft-versus-host disease ( GVHD ) patient treat regimen . - Determine toxicity regimen patient . - Determine overall disease-free survival patient treat regimen . - Correlate change T-cell population clinical outcome , survival , patient treat regimen . - Correlate change T-cell population incidence GVHD , use immunosuppressive agent , effect fludarabine patient treated regimen . - Determine degree chimerism allogeneic PBSC transplantation time course establish patient treated regimen . OUTLINE : This multicenter study . Patients receive melphalan IV 15 minute day -1 . Autologous peripheral blood stem cell ( PBSCs ) reinfused day 0 . Patients also receive sargramostim ( GM-CSF ) subcutaneously ( SC ) IV least 30 minute daily begin day 1 continue blood count recover . Beginning 100-182 day autologous PBSC transplantation , patient receive fludarabine IV 30 minute day -6 -2 cyclophosphamide IV 1-2 hour day -3 -2 . Allogeneic PBSCs infuse day 0 . Patients may receive second allogeneic PBSC infusion day 1 . Patients also receive GM-CSF SC IV least 30 minute daily begin day 1 continue blood count recover . Cyclosporine administer IV orally twice daily graft-versus-host disease ( GVHD ) prophylaxis , begin day -1 continue day 60 , follow taper absence GVHD . Patients follow 5 year . PROJECTED ACCRUAL : A total 19-46 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma meeting 1 follow criterion : Bone marrow plasmacytosis least 10 % plasma cell Sheets plasma cell Biopsyproven plasmacytoma Meets least 1 follow criterion : Presence myeloma ( M ) protein serum Presence Mprotein urine Radiographic evidence osteolytic lesion Generalized osteoporosis allow least 20 % plasma cell bone marrow No nonsecretory myeloma Prior Mprotein serum urine allow provided patient complete remission Must receive conventionaldose chemotherapy initial therapy salvage therapy Must HLAA , B , DR genotypically identical sibling donor PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : AST great 3 time upper limit normal Bilirubin le 2.0 mg/dL Renal : Not specify Cardiovascular : LVEF great 40 % rest symptomatic cardiac disease present Pulmonary : DLCO great 50 % predict ( correct hemoglobin ) symptomatic pulmonary disease present Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior autologous allogeneic peripheral blood stem cell bone marrow transplantation Chemotherapy : See Disease Characteristics More 28 day since prior chemotherapy ( include primary chemotherapy hematopoietic stem cell collection ) No concurrent cytotoxic chemotherapy autologous allogeneic transplantation Endocrine therapy : Prior dexamethasone corticosteroid allow Concurrent corticosteroid autologous allogeneic transplantation allow Radiotherapy : Concurrent radiotherapy autologous allogeneic transplantation allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>